Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 3;14(11):1176.
doi: 10.3390/diagnostics14111176.

Patient-Reported Outcome Measures in Patients with and without Non-Expandable Lung Secondary to Malignant Pleural Effusion-A Single-Centre Observational Study

Jesper Koefod Petersen  1   2 , Katrine Fjaellegaard  1   2 , Daniel Bech Rasmussen  1   2 , Gitte Alstrup  1 , Asbjørn Høegholm  1 , Jatinder Sing Sidhu  1 , Rahul Bhatnagar  3   4   5 , Paul Frost Clementsen  1   6 , Christian B Laursen  3   5 , Uffe Bodtger  1   2
Affiliations

Patient-Reported Outcome Measures in Patients with and without Non-Expandable Lung Secondary to Malignant Pleural Effusion-A Single-Centre Observational Study

Jesper Koefod Petersen et al. Diagnostics (Basel). .

Abstract

Background: Malignant pleural effusion (MPE) affects up to 15% of patients with malignancy, and the prevalence is increasing. Non-expandable lung (NEL) complicates MPE in up to 30% of cases. However, it is not known if patients with malignant pleural effusion and NEL are more symptomatic in activities of daily living compared to patients with MPE with expandable lung.

Methods: This was an observational study on consecutively recruited patients with MPE from our pleural clinic. Before thoracentesis, patients completed patient-reported outcomes on cancer symptoms (ESAS), health-related quality of life (5Q-5D-5L), and dyspnoea scores. Following thoracentesis, patients scored dyspnoea relief and symptoms during thoracentesis. Data on focused lung ultrasound and pleural effusion biochemistry were collected. The non-expandable lung diagnosis was made by pleural experts based on radiological and clinical information.

Results: We recruited 43 patients, including 12 with NEL (28%). The NEL cohort resembled those from previous studies concerning ultrasonography, pleural fluid biochemistry, and fewer cases with high volume thoracentesis. Patients with and without NEL were comparable concerning baseline demography. The 5Q-5D-5L utility scores were 0.836 (0.691-0.906) and 0.806 (0.409-0.866), respectively, for patients with and without NEL. We observed no between-group differences in symptom burden or health-related quality of life.

Conclusion: While the presence of NEL affects the clinical management of recurrent MPE, the presence of NEL seems not to affect patients' overall symptom burden in patients with MPE.

Keywords: malignant pleural effusion; non-expandable lung; patient-reported outcomes; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Patient inclusion.
Figure 2
Figure 2
EQ-5D-5L reported by dimension and level.
Figure 3
Figure 3
Kaplan–Meier survival graph.
See this image and copyright information in PMC

References

    1. Porcel J.M., Gasol A., Bielsa S., Civit C., Light R.W., Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015;20:654–659. doi: 10.1111/resp.12496. - DOI - PubMed
    1. Arnold D.T., De Fonseka D., Perry S., Morley A., Harvey J.E., Medford A., Brett M., Maskell N.A. Investigating unilateral pleural effusions: The role of cytology. Eur. Respir. J. 2018;52:1801254. doi: 10.1183/13993003.01254-2018. - DOI - PubMed
    1. Bibby A.C., Dorn P., Psallidas I., Porcel J.M., Janssen J., Froudarakis M., Subotic D., Astoul P., Licht P., Schmid R., et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur. Respir. J. 2018;52:1800349. doi: 10.1183/13993003.00349-2018. - DOI - PubMed
    1. Bodtger U., Hallifax R.J. Pleural Diseases ERS Monograph. ERS; Sheffield, UK: 2020. Epidemiology: Why is pleural disease becoming more common?
    1. Dresler C.M., Olak J., Herndon J.E., Richards W.G., Scalzetti E., Fleishman S.B., Kernstine K.H., Demmy T., Jablons D.M., Kohman L., et al. Phase III Intergroup Study of Talc Poudrage vs. Talc Slurry Sclerosis for Malignant Pleural Effusion. Chest. 2005;127:909–915. doi: 10.1378/chest.127.3.909. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources